\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes HealthThe European Health and Digital Executive Agency (HaDEA) has launched the following calls for tenders:
- A call for tender to organise training programmes for health specialists on the development, implementation, monitoring and evaluation of national and EU preparedness plans. The objective of this call is to support the enhancement of existing pandemic preparedness capacities and capabilities coupled with a comprehensive and transparent framework for reporting and assessment. Deadline: 23 September 2022. More information is available here.
- A call for tenders for Multiple Framework Contracts in cascade to support expert groups in the field of health in 2023-2025. The objective of this call for tenders is to support the management of the Commission health expert groups and their policy development and actions on key public health challenges through managerial, administrative, technical, scientific and dissemination services. Deadline: 7 October 2022. More information is available here.
Background information: The EU4Health programme will bring a contribution to Europe's long-term public health challenges by building stronger, more resilient and more accessible health systems. It has a €5.3 billion budget during the 2021-27 period.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
